GlassScriptPhysician profile
Douglas Fritz
NPI 1336360742
$9,554.25
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $1,810 · 2021: $3,242 · 2022: $2,603 · 2024: $21.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,362.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,284.21 | 2019-2024 | Farxiga |
| Abbvie INC. | $1,027.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $649.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.12 | 2019-2022 | |
| Novo Nordisk INC | $520.20 | 2020-2022 | |
| Amgen INC. | $434.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $410.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $402.15 | 2020-2022 | |
| Lilly USA, LLC | $334.79 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $272.26 | 2019-2022 | |
| Astellas Pharma US INC | $268.19 | 2019-2022 | |
| Amarin Pharma, INC. | $239.38 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $236.68 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.49 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $174.57 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.17 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $142.74 | 2021 | |
| Allergan, INC. | $137.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.97 | 2019-2022 | |
| Seqirus USA INC | $79.01 | 2022 | |
| Esperion Therapeutics, INC. | $67.80 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.21 | 2022 | |
| Abbott Laboratories | $56.75 | 2019-2021 | |
| Antares Pharma, INC. | $52.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $52.27 | 2019-2021 | |
| Gilead Sciences, INC. | $47.65 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $44.08 | 2019 | |
| Acerus Pharmaceuticals Corporation | $33.65 | 2021-2022 | |
| Redhill Biopharma INC. | $32.55 | 2020 | |
| Genentech USA, INC. | $23.18 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.02 | 2022 | |
| Zealand Pharma US, INC. | $19.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.77 | 2019 | |
| Kaleo, INC. | $13.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Fritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.